Literature DB >> 19280348

The abbreviated impactor measurement (AIM) concept: part 1--Influence of particle bounce and re-entrainment-evaluation with a "dry" pressurized metered dose inhaler (pMDI)-based formulation.

J P Mitchell1, M W Nagel, V Avvakoumova, H MacKay, R Ali.   

Abstract

The abbreviated impactor measurement concept is a potential improvement to the labor-intensive full-resolution cascade impactor methodology for inhaler aerosol aerodynamic particle size distribution (APSD) measurement by virtue of being simpler and therefore quicker to execute. At the same time, improved measurement precision should be possible by eliminating stages upon which little or no drug mass is collected. Although several designs of abbreviated impactor systems have been developed in recent years, experimental work is lacking to validate the technique with aerosols produced by currently available inhalers. In part 1 of this two-part article that focuses on aerosols produced by pressurized metered dose inhalers (pMDIs), the evaluation of two abbreviated impactor systems (Copley fast screening Andersen impactor and Trudell fast screening Andersen impactor), based on the full-resolution eight-stage Andersen nonviable cascade impactor (ACI) operating principle, is reported with a formulation producing dry particles. The purpose was to investigate the potential for non-ideal collection behavior associated with particle bounce in relation to internal losses to surfaces from which particles containing active pharmaceutical ingredient are not normally recovered. Both abbreviated impactors were found to be substantially equivalent to the full-resolution ACI in terms of extra-fine and fine particle and coarse mass fractions used as metrics to characterize the APSD of these pMDI-produced aerosols when sampled at 28.3 L/min, provided that precautions are taken to coat collection plates to minimize bounce and entrainment.

Mesh:

Substances:

Year:  2009        PMID: 19280348      PMCID: PMC2663692          DOI: 10.1208/s12249-009-9202-9

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  14 in total

1.  The role of inertial particle collectors in evaluating pharmaceutical aerosol delivery systems.

Authors:  V A Marple; B A Olson; N C Miller
Journal:  J Aerosol Med       Date:  1998

2.  Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part I: Design.

Authors:  Virgil A Marple; Daryl L Roberts; Francisco J Romay; Nicholas C Miller; Keith G Truman; Michiel Van Oort; Bo Olsson; Michael J Holroyd; Jolyon P Mitchell; Dieter Hochrainer
Journal:  J Aerosol Med       Date:  2003

3.  Considerations for the development and practice of cascade impaction testing, including a mass balance failure investigation tree.

Authors:  Dave Christopher; Paul Curry; Bill Doub; Kenneth Furnkranz; Martin Lavery; Karl Lin; Svetlana Lyapustina; Jolyon Mitchell; Brian Rogers; Helen Strickland; Terrence Tougas; Yi Tsong; Bruce Wyka
Journal:  J Aerosol Med       Date:  2003

4.  Relationship of stage mensuration data to the performance of new and used cascade impactors.

Authors:  Daryl L Roberts; Francisco J Romay
Journal:  J Aerosol Med       Date:  2005

Review 5.  Analysis of cascade impactor mass distributions.

Authors:  Craig Dunbar; Jolyon Mitchell
Journal:  J Aerosol Med       Date:  2005

6.  Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols. Part 3. Final report on a statistical procedure for determining equivalence.

Authors:  David Christopher; Wallace Adams; Anthony Amann; Craig Bertha; Peter R Byron; William Doub; Craig Dunbar; Walter Hauck; Svetlana Lyapustina; Jolyon Mitchell; Beth Morgan; Steve Nichols; Ziqing Pan; Gur Jai Pal Singh; Terrence Tougas; Yi Tsong; Ron Wolff; Bruce Wyka
Journal:  AAPS PharmSciTech       Date:  2007-11-02       Impact factor: 3.246

7.  Assessment of the need to coat particle collection cups of the NGI to mitigate droplet bounce when evaluating nebuliser-produced droplets.

Authors:  E Berg; P Lamb; A Ali; J Dennis; M Tservistas; J Mitchell
Journal:  Pharmeur Sci Notes       Date:  2008-02

8.  Effect of drug load and plate coating on the particle size distribution of a commercial albuterol metered dose inhaler (MDI) determined using the Andersen and Marple-Miller cascade impactors.

Authors:  M M Nasr; D L Ross; N C Miller
Journal:  Pharm Res       Date:  1997-10       Impact factor: 4.200

9.  Particle size distribution of single and multiple sprays of salbutamol metered-dose inhalers (MDIs).

Authors:  S J Graham; R C Lawrence; E D Ormsby; R K Pike
Journal:  Pharm Res       Date:  1995-09       Impact factor: 4.200

10.  Pharmaceutical transition to non-CFC pressurized metered dose inhalers.

Authors:  A Cripps; M Riebe; M Schulze; R Woodhouse
Journal:  Respir Med       Date:  2000-06       Impact factor: 3.415

View more
  9 in total

1.  Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated andersen cascade impactors (ACIs): part 1.

Authors:  Jolyon P Mitchell; Mark W Nagel; Cathy C Doyle; Rubina S Ali; Valentina I Avvakoumova; J David Christopher; Jorge Quiroz; Helen Strickland; Terrence Tougas; Svetlana Lyapustina
Journal:  AAPS PharmSciTech       Date:  2010-05-18       Impact factor: 3.246

2.  Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated andersen cascade impactors (ACIs): part 2--investigation of bias in extra-fine mass fraction with AIM-HRT impactor.

Authors:  Jolyon P Mitchell; Mark W Nagel; Cathy C Doyle; Rubina S Ali; Valentina I Avvakoumova; J David Christopher; Jorge Quiroz; Helen Strickland; Terrence Tougas; Svetlana Lyapustina
Journal:  AAPS PharmSciTech       Date:  2010-07-10       Impact factor: 3.246

3.  The abbreviated impactor measurement (AIM) concept: part II--Influence of evaporation of a volatile component-evaluation with a "droplet-producing" pressurized metered dose inhaler (pMDI)-based formulation containing ethanol as cosolvent.

Authors:  J P Mitchell; M W Nagel; V Avvakoumova; H MacKay; R Ali
Journal:  AAPS PharmSciTech       Date:  2009-03-17       Impact factor: 3.246

4.  Evaluation of an abbreviated impactor for fine particle fraction (FPF) determination of metered dose inhalers (MDI).

Authors:  Changning Guo; Diem Ngo; Shafiq Ahadi; William H Doub
Journal:  AAPS PharmSciTech       Date:  2013-06-19       Impact factor: 3.246

5.  Improved quality control metrics for cascade impaction measurements of orally inhaled drug products (OIPs).

Authors:  Terrence P Tougas; David Christopher; Jolyon P Mitchell; Helen Strickland; Bruce Wyka; Mike Van Oort; Svetlana Lyapustina
Journal:  AAPS PharmSciTech       Date:  2009-10-29       Impact factor: 3.246

6.  Product lifecycle approach to cascade impaction measurements.

Authors:  Terrence P Tougas; Dave Christopher; Jolyon Mitchell; Svetlana Lyapustina; Michiel Van Oort; Richard Bauer; Volker Glaab
Journal:  AAPS PharmSciTech       Date:  2011-02-01       Impact factor: 3.246

7.  In Vivo-Relevant Transwell Dish-Based Dissolution Testing for Orally Inhaled Corticosteroid Products.

Authors:  Masahiro Sakagami; Hua Li; Jügen Venitz
Journal:  Pharm Res       Date:  2019-05-09       Impact factor: 4.200

8.  The effect of nonideal cascade impactor stage collection efficiency curves on the interpretation of the size of inhaler-generated aerosols.

Authors:  D L Roberts; J P Mitchell
Journal:  AAPS PharmSciTech       Date:  2013-03-19       Impact factor: 3.246

9.  Comparison of samplers collecting airborne influenza viruses: 1. Primarily impingers and cyclones.

Authors:  Peter C Raynor; Adepeju Adesina; Hamada A Aboubakr; My Yang; Montserrat Torremorell; Sagar M Goyal
Journal:  PLoS One       Date:  2021-01-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.